Natera Reports Strong Q4 & FY25 Revenue Growth, Gross Margin Expansion, and Positive 2026 Outlook

summarizeSummary

Natera, Inc. announced strong Q4 and full year 2025 financial results, featuring significant revenue growth, improved gross margins, and positive cash inflow, alongside an optimistic 2026 financial outlook.

check_boxKey Events

• Strong Q4 and Full Year 2025 Revenue Growth

  Total revenues increased by 39.8% in Q4 2025 to $665.5 million and by 35.9% for the full year to $2.306 billion, driven by product revenue increases.

• Gross Margin Expansion

  Gross margin improved to 66.9% in Q4 2025, up from 62.9% in Q4 2024, and reached 64.7% for the full year 2025, compared to 60.3% in FY 2024.

• Significant Oncology Test Volume Increase

  Oncology tests processed grew by 54.7% in Q4 2025 and 51.6% for the full year 2025, highlighting strong adoption in this segment.

• Positive Cash Inflow for Full Year 2025

  The company achieved a positive cash inflow of approximately $107.6 million for the full year 2025.

auto_awesomeAnalysis

Natera's latest earnings report signals robust operational performance and a positive trajectory for the company. The significant year-over-year revenue growth in both the fourth quarter and full year 2025, coupled with expanding gross margins, demonstrates strong demand for its genetic testing products, particularly in oncology. Achieving positive cash inflow for the full year is a crucial financial milestone, providing flexibility for continued investment. The 2026 financial guidance, projecting further substantial revenue growth and positive cash flow, reinforces management's confidence in the company's market position and future prospects. Investors should view this report as a strong indicator of Natera's continued execution and growth potential.